Endothelial progenitor cells and dysfunctional vascular endothelium (EPC/ED)

Endothelial progenitor cells (EPCs) are bone marrow-derived cells that circulate in the peripheral blood and possess the ability to differentiate into mature endothelial cells, playing a vital role in postnatal vasculogenesis and the maintenance of vascular integrity (Asahara et al., Science 1997). Dysfunctional vascular endothelium is a systemic condition characterized by impaired vasodilation, increased oxidative stress, and a pro-inflammatory state, which serves as a primary driver for the development of atherosclerosis and cardiovascular disease (Deanfield et al., Circulation 2007). The relationship between EPCs and the endothelium is symbiotic; EPCs act as a cellular reservoir for repairing damaged vessel walls, and their depletion or functional impairment is a hallmark of endothelial dysfunction (Werner et al., NEJM 2005). Therapeutic interventions aim to restore vascular health by either mobilizing endogenous EPCs using drugs like statins and growth factors or by improving the local environment of the dysfunctional endothelium to enhance cell homing and survival (Landmesser et al., Circulation 2004). Monitoring EPC levels and endothelial function serves as a significant prognostic indicator for cardiovascular risk and the efficacy of vasoprotective treatments.

Other names

EPCsEndothelial dysfunctionVascular endothelial dysfunctionEndothelial progenitor cell-mediated repair

Pharmacological agents like statins and ACE inhibitors improve endothelial function by increasing nitric oxide bioavailability and reducing oxidative stress, while also promoting the mobilization and homing of endothelial progenitor cells from the bone marrow to sites of vascular injury (Landmesser et al., Circulation 2004; Werner et al., NEJM 2005).